Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 8:14:2389-2397.
doi: 10.2147/CMAR.S326114. eCollection 2022.

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective

Takashi Matsumoto  1 , Masaki Shiota  1 , Leandro Blas  1 , Masatoshi Eto  1
Affiliations
Review

Role of Olaparib in the Management of Metastatic Castration-Resistant Prostate Cancer: A Japanese Clinician's Perspective

Takashi Matsumoto et al. Cancer Manag Res. .

Abstract

Several studies have identified various targetable genomic alterations in prostate cancer, which accumulate during carcinogenesis and cancer progression. Genomic alterations in genes involved in DNA damage repair by homologous recombination repair may predict increased sensitivity to poly-ADP ribose polymerase (PARP) inhibitors. The Phase 3 PROfound trial has shown that treatment with the PARP inhibitor olaparib was associated with an improved radiographic progression-free survival and overall survival among patients with homologous recombination repair-deficient metastatic castration-resistant prostate cancer (mCRPC) after the treatment with androgen receptor targeting therapy, especially in men with BRCA1 or BRCA2 mutation. In Japan, olaparib was approved in December 2020 for the treatment of mCRPC with BRCA1 or BRCA2 mutation. In addition, genetic tests to detect BRCA1 or BRCA2 mutation to select patients who are likely to benefit from olaparib were also approved. This review summarizes the status of olaparib treatment for mCRPC, focusing on the situation in Japan.

Keywords: BRCA; Japanese; companion diagnosis; genomic profile; metastatic castration-resistant prostate cancer; olaparib.

PubMed Disclaimer

Conflict of interest statement

Masaki Shiota received honoraria from Janssen Pharmaceutical, AstraZeneca, Astellas Pharma, Sanofi, and Bayer Yakuhin and research funding support from Daiichi Sankyo. Masatoshi Eto received honoraria from Ono Pharmaceutical, Takeda Pharmaceutical, Novartis Pharma, Pfizer, Bristol-Myers Squibb, Janssen Pharmaceutical, MSD, Merck Biopharma, AstraZeneca, and Eisai and research funding support from Sanofi, Bayer Yakuhin, Astellas Pharma, Ono Pharmaceutical, and Takeda Pharmaceutical. The authors report no other conflicts of interest in this work.

References

    1. Huggins C. Prostatic cancer treated by orchiectomy: the five year results. J Am Med Assoc. 1946;131(7):576–581. doi:10.1001/jama.1946.02870240008003 - DOI - PubMed
    1. Ryan CJ, Tindall DJ. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J Clin Oncol. 2011;29(27):3651–3658. doi:10.1200/JCO.2011.35.2005 - DOI - PubMed
    1. Galletti G, Leach BI, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2017;57:16–27. doi:10.1016/j.ctrv.2017.04.008 - DOI - PubMed
    1. Abeshouse A, Ahn J, Akbani R, et al. The molecular taxonomy of primary prostate cancer. Cell. 2015;163(4):1011–1025. doi:10.1016/j.cell.2015.10.025 - DOI - PMC - PubMed
    1. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161(5):1215–1228. doi:10.1016/j.cell.2015.05.001 - DOI - PMC - PubMed